The effectiveness of the locoregional treatment using hepatic arterial infusion chemotherapy for locally progressed hepatocellular carcinoma

Various locoregional treatment and molecular targeted agents (MTAs) are used for hepatocellular carcinoma (HCC). Establishing the multidisciplinary therapeutic strategy with locoregional treatment and MTAs is important.
We compared two therapeutic strategies, locoregional treatment using hepatic arterial infusion chemotherapy (HAIC) based multidisciplinary therapeutic strategy (loco) and MTA based therapeutic strategy (MTA).
We corrected 1,624 patients with HCC from 10 facilities conducted HAIC and from 15 facilities that didn’t conduct the HAIC. We evaluated the various HCC ; cohort1 [without  macrovascular invasion (MVI) and extrahepatic spread (EHS)], cohort2 (with MVI/without EHS), cohort 3 (without MVI/with EHS) and cohort4 (with MVI/EHS). We evaluated HCC with severe MVI (Vp3/4); without (cohort5) and with (cohort6) EHS.
In the cohort1, each MST of loco and MTA group is 18 and 15 months (n.s.). In the cohort2, the MSTs of loco and MTA groups are 13 and 8 (p<0.001). In the cohort3, the MSTs of loco and MTA groups are 6 and 11 (p<0.05). In the cohort4, the MSTs of loco and MTA groups are 7 and 5 (n.s.). The MSTs of loco and MTA groups are 10 and 5 in the cohort5 (p<0.001). In the cohort6, the MSTs of loco and MTA groups are 5 and 4 (p<0.05).
Locoregional treatment using HAIC based multidisciplinary therapeutic strategy is effective for locally progressed HCC even with EHS.